Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: Toxicity and adherence

Journal of Correctional Health Care

Volumn 18, Issue 2, 2012, Pages 131-142

  White, Mary C ^a   Tulsky, Jacqueline P ^b   Lee, Ju Ruey Jiuan ^c,d   Chen, Lisa ^a   Goldenson, Joe ^e   Spetz, Joanne ^a   Kawamura, L Masae ^f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d Scientific Analysis Lumetra   (United States)

^e SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^f Quiagen   (United States)

^g Tuberculosis Control Division   (United States)

Author keywords

correctional health care; isoniazid; preventive therapy; rifampin; tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; FEMALE; HUMAN; LATENT TUBERCULOSIS; LIVER FUNCTION TEST; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRISON; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOCIOECONOMICS;

ADULT; ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; FEMALE; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; LIVER FUNCTION TESTS; MALE; MEDICATION ADHERENCE; PRISONS; RIFAMPIN; SOCIOECONOMIC FACTORS;

EID: 84860849228     PISSN: 10783458     EISSN: 19405200     Source Type: Journal    
DOI: 10.1177/1078345811435973     Document Type: Review

References (32)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection.Morbidity and Mortality Weekly Report. 2000;49:1-51.
2. Barnes P.F.,el-Hajj H.,Preston-Martin S.,Cave M.D.,Jones B.E.,Otaya M.,Eisenach K.D.Transmission of tuberculosis among the urban homeless.Journal of the American Medical Association. 1996;275:305-307.
3. Severe isoniazid-associated hepatitis-New York, 1991-1993.Morbidity and Mortality Weekly Report. 1993;42:545-547.
4. Prevention and control of tuberculosis in correctional and detention facilities: Recommendations from CDC.Morbidity and Mortality Weekly Report. 2006;55:1-44.
5. Fountain F.F.,Tolley E.,Chrisman C.R.,Self T.H.Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: A 7-year evaluation from a public health tuberculosis clinic.Chest. 2005;128:116-123.
6. Fountain F.F.,Tolley E.A.,Jacobs A.R.,Self T.H.Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection.American Journal of Medical Science. 2009;337:317-320.
7. Glaser J.,Greifinger R.Correctional health care: A public health opportunity.Annals of Internal Medicine. 1993;118:139-145.
8. Greenberg G.A.,Rosenheck R.A.Jail incarceration, homelessness, and mental health: A national study.Psychiatric Services. 2008;59:170-177.
9. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong.American Review of Respiratory Diseases. 1992;145:36-41.
10. Horsburgh C.R.,Goldberg S.,Bethel J.,Chen S.,Colson P.W.,Hirsch-Moverman Y.Latent tuberculosis infection treatment acceptance and completion in the United States and Canada.Chest. 2010;137:401-409.
11. Lardizabal A.,Passannante M.,Kojakali F.,Hayden C.,Reichman L.B.Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.Chest. 2006;130:1712-1717.
12. Martínez E.,Collazos J.,Mayo J.Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions.Medicine. 1999;78:361-369.
13. Maruschak L.M.HIV in prisons and jails, 2002. Washington, DC: Bureau of Justice Statistics; 2004:.
14. Maruschak L.M.Medical problems of jail inmates. Washington, DC: Bureau of Justice Statistics; 2006:.
15. Menzies D.,Dion M.J.,Rabinovitch B.,Mannix S.,Brassard P.,Schwartzman K.Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.American Journal of Respiratory and Critical Care Medicine. 2004;170:445-449.
16. Menzies D.,Long R.,Trajman A.,Dion M.J.,Yang J.,Al Jahdali H.,Schwartzman K.Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial.Annals of Internal Medicine. 2008;149:689-697.
17. Minton T.D.,Sabol W.J.Jail inmates at midyear 2008-Statistical tables. Washington, DC: Bureau of Justice Statistics; 2009:.
18. Nolan C.M.,Goldberg S.V.,Buskin S.E.Hepatotoxicity associated with isoniazid preventive therapy: A 7-year study from a public health tuberculosis clinic.Journal of the American Medical Association. 1999;281:1014-1018.
19. Page K.R.,Sifakis F.,Montes de Oca R.,Cronin W.A.,Doherty M.C.,Federline L.,Dorman S.E.Improved adherence and less toxicity with rifampin vs. isoniazid for treatment of latent tuberculosis: A retrospective study.Archives of Internal Medicine. 2006;166:1863-1870.
20. Reichman L.B.,Lardizabal A.,Hayden C.H.Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.American Journal of Respiratory and Critical Care Medicine. 2004;170:832-835.
21. Sabol W.J.,Minton T.D.Jail inmates at midyear 2007. Washington, DC: Bureau of Justice Statistics; 2008:.
22. Saukkonen J.J.,Cohn D.L.,Jasmer R.M.,Schenker S.,Jereb J.A.,Nolan C.M.An official ATS statement: Hepatotoxicity of antituberculosis therapy.American Journal of Respiratory and Critical Care Medicine. 2006;174:935-952.
23. Shieh F.K.,Snyder G.,Horsburgh C.R.,Bernardo J.,Murphy C.,Saukkonen J.J.Predicting non-completion of treatment for latent tuberculous infection: A prospective survey.American Journal of Respiratory and Critical Care Medicine. 2006;174:717-721.
24. Sterling T.R.New approaches to the treatment of latent tuberculosis.Seminars in Respiratory and Critical Care Medicine. 2008;29:532-541.
25. Medical management of vulnerable and underserved patients: Principles, practice and populations.
26. White M.C.,Gournis E.,Kawamura M.,Menendez E.,Tulsky J.P.Effect of directly observed preventive therapy for latent tuberculosis infection in San Francisco.International Journal of Tuberculosis and Lung Disease. 2003;7:30-35.
27. White M.C.,Tulsky J.P.,Estes M.,Jamison R.,Long H.L.Health and health behaviors in HIV-infected jail inmates, 1999 and 2005.AIDS Patient Care and STDs. 2008;22:221-231.
28. White M.C.,Tulsky J.P.,Goldenson J.,Portillo C.J.,Kawamura M.,Menendez E.Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail.Archives of Internal Medicine. 2002;162:1044-1050.
29. White M.C.,Tulsky J.P.,Menendez E.,Goldenson J.,Kawamura L.M.Incidence of TB in inmates with latent TB infection: 5-year follow-up.American Journal of Preventive Medicine. 2005;29:295-301.
30. Wilper A.P.,Woolhandler S.,Boyd J.W.,Lasser K.E.,McCormick D.,Bor D.H.,Himmelstein D.U.The health and health care of U.S. prisoners: Results of a nationwide survey.American Journal of Public Health. 2009;99:666-672.
31. Young H.,Wessolossky M.,Ellis J.,Kaminski M.,Daly J.S.A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central Massachusetts.Clinical Infectious Diseases. 2009;49:424-427.
32. Ziakas P.D.,Mylonakis E.4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: A meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.Clinical Infectious Diseases. 2009;49:1883-1889.